AVIR
Atea Pharmaceuticals, Inc.
There isn't enough reported data to score AVIR yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AVIR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Stable | |
| Unavailable | |
| Healthy |
AVIR's balance sheet is currently healthy, and its profitability is stable. There isn't enough data to rate its revenue and cash flow.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AVIR PE Valuation
AVIR has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AVIR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect AVIR's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AVIR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.95 | -$0.18 |
| Q2 2026 | -$2.08 | -$0.47 |
| Q1 2026 | -$2.11 | -$0.46 |
| Q4 2025 | -$1.94 | +$0.06 |
| Q3 2025 | -$1.77 | +$0.29 |
| Q2 2025 | -$1.61 | +$0.48 |
| Q1 2025 | -$1.65 | +$0.30 |
| Q4 2024 | -$2.00 | -$0.37 |
AVIR lost $1.95 per share over the past year, a bigger loss than the year before.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
AVIR Quarterly Revenue
AVIR and HIMS do not have enough comparable growth data to identify a winner.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2021 | 63% | N/A |
| Q3 2021 | -68% | N/A |
| Q2 2021 | 14% | N/A |
| Q1 2021 | 46% | N/A |
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
AVIR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$28.9M | +$11.5M |
| Q2 2026 | -$37.1M | -$4.2M |
| Q1 2026 | -$46.4M | -$15.8M |
| Q4 2025 | -$28.2M | +$2.2M |
| Q3 2025 | -$40.4M | -$17.3M |
| Q2 2025 | -$32.9M | +$9.3M |
| Q1 2025 | -$30.6M | +$9.3M |
| Q1 2022 | -$59.1M | -$42.2M |
AVIR has burned cash in almost every quarter: −$141M over the past year, against −$134M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over AVIR on cash generation, producing positive trailing cash flow while its opponent burns cash.
AVIR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +174K shares |
| 1 year | +1.5% | +1.2M shares |
| 3 years | -3.8% | -3.2M shares |
| 5 years | -3.1% | -2.6M shares |
| Available history | +70% | +32.9M shares |
AVIR has 80M diluted shares, up 1.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | $11.4M |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over AVIR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
AVIR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -5.8x | Net Cash |
| Q2 2022 | -27.8x | Net Cash |
| Q1 2022 | -10.8x | Net Cash |
| Q4 2021 | -5.5x | Net Cash |
| Q3 2021 | -22.2x | Net Cash |
| Q2 2021 | -19.3x | Net Cash |
| Q1 2021 | -35.2x | Net Cash |
AVIR has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AVIR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.5 | Neutral |
| Stochastic | 15.8 | Oversold |
AVIR's weekly RSI is 41 (neutral) and its Stochastic is 16 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AVIR PE vs Healthcare Sector
| Metric | AVIR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
AVIR has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
AVIR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.56 | 7.7% below |
| 20 week MA | $4.92 | 14% below |
| 50 week MA | $4.70 | 10% below |
| 100 week MA | $3.93 | 7.1% above |
| 200 week MA | $3.76 | 12% above |
AVIR has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AVIR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $30.3 | $34.5 | +14% |
| 2021 | $34.5 | $9.11 | -74% |
| 2022 | $9.11 | $4.59 | -50% |
| 2023 | $4.59 | $3.05 | -34% |
| 2024 | $3.05 | $3.33 | +9.2% |
| 2025 | $3.33 | $3.65 | +9.6% |
| 2026 YTD | $3.65 | $4.21 | +15% |
AVIR has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.